Highlights WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
13.48 ^HKD	+5.81%		+6.81%	-54.46%

Apr. 01	Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	CI
Mar. 27	WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	Mar. 27	MT
WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses	Mar. 26	DJ
WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
WuXi AppTec's Shares Fall After Downbeat Guidance	Mar. 19	DJ
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat	Mar. 18	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	Mar. 14	RE
Biotech trade association to split with China's WuXi AppTec	Mar. 13	RE
WuXi Companies' Shares Rise on Receding Worries About Potential U.S. Sanctions	Mar. 04	DJ
Wuxi Biologics Says It Is Not a Wuxi AppTec Subsidiary Amid US Security Risk Probe	Feb. 13	MT
WuXi Companies' Shares Slide Amid Concerns Over Proposed U.S. Bill	Feb. 02	DJ
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland	Jan. 31	CI
WuXi Biologics Launches WuXia ADCC PLUS? for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect	Jan. 24	CI
WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody?	Jan. 16	CI
Wuxi Biologics Shares Rise After Jump in December Projects	Jan. 11	DJ
WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates	Jan. 10	CI
Wuxi Biologics Announces to Increase Manufacturing Capacity in Massachusetts	Jan. 08	CI
WuXi Biologics Inc. commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.	Dec. 07	CI
WuXi Biologics Launches $600 Million Share Buyback Program	Dec. 06	MT
Wuxi Biologics Sees Revenue Growing 10% in 2023	Dec. 04	DJ
Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale	Nov. 22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Highlights

Filters